HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis
Paul G. Richardson(Harvard University), Joan Bladé Creixenti(Hospital Clínic de Barcelona), Olof Harlin(Oncopeptides (Sweden)), Alessandra Larocca(Cornell University), María‐Victoria Mateos(Hospital Clínico San Carlos), Agne Paner(Rush University Medical Center), Johan Harmenberg(Oncopeptides (Sweden)), Noemí Puig(Instituto de Investigación Biomédica de Salamanca), Xavier Leleu(Inserm), Omar Nadeem(Harvard University), Albert Oriol(Institut Català d'Oncologia), Anastasios Raptis(University of Pittsburgh), Elena Zamagni(Istituti di Ricovero e Cura a Carattere Scientifico), Cyrille Touzeau(Centre National de la Recherche Scientifique), Hani Hassoun(Memorial Sloan Kettering Cancer Center), Adrián Alegre Amor(Hospital Universitario Quirónsalud Madrid), Michèle Cavo(Unknown), Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Marcus Thuresson(Statisticon (Sweden)), Amitabha Mazumder(NYU Langone Health), Christopher Maisel(Baylor Medical Center at Garland), John W. Hiemenz(University of Florida), Maxim Norkin(Centre Hospitalier Universitaire Vaudois)
Cited by 11
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k